^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) + Imlygic (talimogene laherparepvec) (GM-CSF agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PD11-04 Primary results of SOLTI-1503 PROMETEO phase 2 trial of Combination of Talimogene Laherparepvec (T-VEC) with Atezolizumab in patients with residual breast cancer after standard neoadjuvant multi-agent chemotherapy
Published date:
11/22/2022
Excerpt:
The pCR rate was 30% in HR+/HER2- disease and 12.5 % in TNBC….Two months of T-VEC in combination with atezolizumab induced a pCR in a subgroup of pts with chemoresistant HER2- breast cancer.
Trial ID:
